<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481310</url>
  </required_header>
  <id_info>
    <org_study_id>NU 14H09</org_study_id>
    <secondary_id>NCI-2015-00400</secondary_id>
    <secondary_id>X16042</secondary_id>
    <secondary_id>STU00200596</secondary_id>
    <secondary_id>NU 14H09</secondary_id>
    <secondary_id>P30CA060553</secondary_id>
    <nct_id>NCT02481310</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects, good and bad of a new drug called&#xD;
      ixazomib (also called MLN9708), when it is given along with a common treatment combination,&#xD;
      called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for short). This is a type of study called a phase&#xD;
      I/II trial. In the phase I part, the dose of the study drug (ixazomib) will be adjusted&#xD;
      (either up or down) to find the maximum (highest) dose that does not cause excessive (too&#xD;
      many) harmful side effects. In the phase II part, this dose of ixazomib will be given at the&#xD;
      maximum safe dose found in phase I. In both phase I and II, DA-EPOCH-R will be adjusted&#xD;
      between cycles depending on how blood cell levels are affected between cycles. Ixazomib is&#xD;
      considered investigational because it is not approved by the U.S. Food and Drug&#xD;
      Administration (FDA). DA-EPOCH-R is a combination chemotherapy treatment developed over the&#xD;
      last 14-15 years, and each of the drugs in this regimen is FDA-approved and considered part&#xD;
      of the standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the safety of ixazomib (ixazomib citrate) given with dose-adjusted etoposide,&#xD;
      prednisone, vincristine (vincristine sulfate), cyclophosphamide, doxorubicin (doxorubicin&#xD;
      hydrochloride), and rituximab (DA-EPOCH-R) in patients with aggressive, v-myc avian&#xD;
      myelocytomatosis viral oncogene homolog (MYC)-aberrant lymphoid malignancies, and to&#xD;
      determine the recommended phase II dose (RP2D) of the combination. (Phase I) II. To evaluate&#xD;
      the efficacy, as measured by 12-month progression free survival (PFS), of ixazomib given with&#xD;
      DA-EPOCH-R in patients with aggressive, MYC-aberrant lymphoid malignancies. (Phase II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Further evaluate the frequency and severity of toxicity. II. Further evaluate the clinical&#xD;
      efficacy, as measured by response rate and overall survival (OS).&#xD;
&#xD;
      III. Assess the predictive value of fludeoxyglucose F-18 (FDG)-positron emission tomography&#xD;
      (PET)/computed tomography (CT) scans on PFS.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the impact of cell of origin (COO) upon response rate, PFS, and OS.&#xD;
&#xD;
      II. Assess the feasibility and outcomes of consolidation stem cell transplant (SCT).&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of ixazomib citrate followed by a phase II&#xD;
      study.&#xD;
&#xD;
      INDUCTION:&#xD;
&#xD;
      Patients receive ixazomib citrate orally (PO) on day 1 and day 8 or 15; etoposide&#xD;
      intravenously (IV), vincristine sulfate IV, and doxorubicin hydrochloride IV continuously&#xD;
      over 96 hours on days 1-4; prednisone PO twice daily (BID) on days 1-5; rituximab IV should&#xD;
      be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum&#xD;
      rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.&#xD;
&#xD;
      CENTRAL NERVOUS SYSTEM (CNS) PROPHYLAXIS:&#xD;
&#xD;
      Patients with a negative lumbar puncture (LP) receive methotrexate intrathecally (IT) once&#xD;
      per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR&#xD;
      cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT&#xD;
      or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.&#xD;
&#xD;
      MAINTENANCE:&#xD;
&#xD;
      Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8,&#xD;
      and 15. Treatment repeats every 28 days for up to one year (or as long as deriving benefit)&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For phase I of the study, the dose-limiting toxicity of ixazomib given with DA-EPOCH-R will be evaluated</measure>
    <time_frame>The first 21 days</time_frame>
    <description>The dose-limiting toxicity (DLT), defined as the occurrence of â‰¥ Grade 3 toxicity experienced during the first cycle (3 weeks or 21 days) of study treatment, will be determined, except for cytopenias. The Maximum Tolerated Dose (MTD) will constitute the RP2D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For phase II of the study, 12-month PFS (Progression Free Survival) of ixazomib given with DA-EPOCH-R will be measured</measure>
    <time_frame>Time elapsed between treatment initiation and tumor progression or death from any cause, assessed at 12 months</time_frame>
    <description>Excluding patients who are lost to follow-up, the 12-month PFS will be defined as the percentage of patients alive and progression free 12 months from start of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicity</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Adverse events will be defined as those included in CTCAE v 4.0. The occurrence of each will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of toxicity</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Adverse events will be defined as those included in CTCAE v 4.0. The severity of each will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate and OS (Overall Survival)</measure>
    <time_frame>At 3 weeks and at 6 weeks</time_frame>
    <description>Anti-tumor activity will be defined as the detection of SD (Stable Disease), Partial Response (PR), or CR (Complete Response) by CT or PET/CT scan, and/or resolution of marrow-only involvement. CR and PR will each be assessed according to the Revised Response Criteria for Malignant Lymphoma. Assessments will be performed after cycles 2 and 6, then at the discretion of the treating investigator. OS will be defined as freedom from death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the predictive value of FDG-PET/CT scans on PFS</measure>
    <time_frame>Up to 1 year after treatment stopped</time_frame>
    <description>Patients will be categorized as either FDG-PET (+) or (-) at interim and end-of treatment imaging.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine the impact of cell of origin (COO) upon response rate, PFS, and OS</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Impact of COO defined as germinal center B-cell (GCB) and non-GCB via the Hans algorithm upon response rate, PFS, and OS (applicable only to patients with DLBCL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Consolidation SCT (Stem cell transplant)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Feasibility and outcomes of consolidation SCT will be assessed. Patients will be grouped by whether consolidative SCT was performed in first remission, with PFS compared across groups (SCT vs. non-SCT).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Adult Burkitt Lymphoma</condition>
  <condition>B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma</condition>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <condition>MYC Gene Mutation</condition>
  <condition>Plasmablastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INDUCTION:&#xD;
Patients receive ixazomib citrate PO on day 1 and day 8 or 15; etoposide IV, vincristine sulfate IV, and doxorubicin hydrochloride IV continuously over 96 hours on days 1-4; prednisone PO BID on days 1-5; rituximab IV should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.&#xD;
CNS PROPHYLAXIS:&#xD;
Patients with a negative LP receive methotrexate IT once per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.&#xD;
MAINTENANCE:&#xD;
Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8, and 15. Treatment repeats every 28 days for up to one year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IT or intraventricularly</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixazomib Citrate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>MLN-9708</other_name>
    <other_name>MLN9708</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IT or intraventricularly</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic Hydrocortisone</intervention_name>
    <description>Given IT or intraventricularly</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>Aeroseb-HC</other_name>
    <other_name>Barseb HC</other_name>
    <other_name>Barseb-HC</other_name>
    <other_name>Cetacort</other_name>
    <other_name>Cort-Dome</other_name>
    <other_name>Cortef</other_name>
    <other_name>Cortenema</other_name>
    <other_name>Cortifan</other_name>
    <other_name>Cortisol</other_name>
    <other_name>Cortispray</other_name>
    <other_name>Cortril</other_name>
    <other_name>Dermacort</other_name>
    <other_name>Domolene</other_name>
    <other_name>Eldecort</other_name>
    <other_name>Hautosone</other_name>
    <other_name>Heb-Cort</other_name>
    <other_name>HYDROCORTISONE</other_name>
    <other_name>Hydrocortone</other_name>
    <other_name>Hytone</other_name>
    <other_name>Komed-HC</other_name>
    <other_name>Nutracort</other_name>
    <other_name>Proctocort</other_name>
    <other_name>Rectoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy, rituximab, ixazomib)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a histological diagnosis of any of the following (all stages&#xD;
             allowed):&#xD;
&#xD;
               -  Diffuse large b-cell lymphoma (DLBCL) (including transformation from a previously&#xD;
                  indolent non-Hodgkin lymphoma [NHL], so long as no prior systemic treatment was&#xD;
                  given for the indolent NHL)&#xD;
&#xD;
               -  B-cell lymphoma, unclassifiable, with features intermediate between diffuse large&#xD;
                  B-cell lymphoma&#xD;
&#xD;
               -  Burkitt lymphoma&#xD;
&#xD;
               -  MYC+ plasmablastic lymphoma by histology&#xD;
&#xD;
          -  Patients must have measurable disease (defined as &gt;= 1.5 cm in diameter)&#xD;
&#xD;
          -  Patients must have MYC-rearrangement, as determined by fluorescent in-situ&#xD;
             hybridization (FISH) (does not require central review)&#xD;
&#xD;
          -  The following results must be available or pending at time of registration, though&#xD;
             results will not affect enrollment/treatment:&#xD;
&#xD;
               -  B-cell chronic lymphocytic leukemia (CLL)/lymphoma (BCL)-2 rearrangement by FISH&#xD;
&#xD;
               -  BCL-6 rearrangement by FISH NOTE: although not required, it is encouraged that&#xD;
                  MYC and BCL-2 be measured by immunohistochemistry (IHC) and clearly documented&#xD;
&#xD;
          -  Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             of 0-3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,000/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 75,000/mm^3&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN); NOTE: exceptions can be granted&#xD;
             from principal investigator (PI) for instances of Gilbert's disease, and/or primarily&#xD;
             indirect bilirubinemia, if due to recent transfusion and/or hemolysis&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SPGT]) =&lt;&#xD;
             3 X institutional ULN&#xD;
&#xD;
          -  Calculated creatinine clearance &gt;= 30 mL/min&#xD;
&#xD;
          -  NOTE: platelet transfusions to help patients meet eligibility criteria are not allowed&#xD;
             within 3 days before registration; these requirements do not apply to those with&#xD;
             marrow involvement of lymphoma (any extent)&#xD;
&#xD;
          -  Female patients must meet one of the following criteria:&#xD;
&#xD;
               -  Postmenopausal for at least 1 year prior to registration&#xD;
&#xD;
               -  Surgically sterile&#xD;
&#xD;
               -  Of childbearing potential and agree to practice 2 effective methods of&#xD;
                  contraception, at the same time, from the time of signing the informed consent&#xD;
                  form through 90 days after the last dose of study drug&#xD;
&#xD;
               -  Of childbearing potential and agree to practice true abstinence when this is in&#xD;
                  line with the preferred and usual lifestyle of the subject NOTE: periodic&#xD;
                  abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and&#xD;
                  withdrawal are not acceptable methods of contraception&#xD;
&#xD;
          -  Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree&#xD;
             to one of the following:&#xD;
&#xD;
               -  Agree to practice effective barrier contraception during the entire study&#xD;
                  treatment period and through 90 days after the last dose of study drug&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject NOTE: periodic abstinence (eg, calendar,&#xD;
                  ovulation, symptothermal, post-ovulation methods) and withdrawal are not&#xD;
                  acceptable methods of contraception&#xD;
&#xD;
          -  Females of child-bearing potential (FOCBP) must have a negative pregnancy test within&#xD;
             # days prior to registration on study&#xD;
&#xD;
          -  Patients must have the ability to understand and the willingness to sign a written&#xD;
             informed consent prior to registration on study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had more than one cycle of prior chemoimmunotherapy for diagnosis of&#xD;
             NHL are not eligible; NOTE: such patients must have fully recovered (ie, =&lt; grade 1&#xD;
             toxicity) from the reversible effects of prior chemotherapy before starting treatment&#xD;
             on the current protocol&#xD;
&#xD;
          -  Patients who have had major surgery within 4 weeks prior to registration are not&#xD;
             eligible&#xD;
&#xD;
          -  Patients who have had radiotherapy within 14 days before registration are not&#xD;
             eligible; NOTE: If the involved field is small, 7 days will be considered a sufficient&#xD;
             interval between treatment and administration of the ixazomib&#xD;
&#xD;
          -  Patients who have an infection requiring systemic antibiotic therapy or other serious&#xD;
             infection within 14 days before study enrollment are not eligible&#xD;
&#xD;
          -  Patients who have evidence of current uncontrolled cardiovascular conditions,&#xD;
             including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic&#xD;
             congestive heart failure, unstable angina, or myocardial infarction within the past 6&#xD;
             months are not eligible&#xD;
&#xD;
          -  Patients who have undergone systemic treatment, within 14 days prior to registration,&#xD;
             with strong inhibitors of cytochrome P450 superfamily (CYP)1A2 (fluvoxamine, enoxacin,&#xD;
             ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin,&#xD;
             itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A&#xD;
             inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital),&#xD;
             or use of Ginkgo biloba or St. John's wort are not eligible&#xD;
&#xD;
          -  Patients who have a clinically active hepatitis B or C virus infection are not&#xD;
             eligible; NOTE: those with evidence of exposure to hepatitis B virus (HBV) may enroll&#xD;
             so long as HBV viral load is negative AND subject is willing/able to take appropriate&#xD;
             antiviral prophylaxis to prevent reactivation&#xD;
&#xD;
          -  Patients with any serious medical or psychiatric illness that could, in the&#xD;
             investigator's opinion, potentially interfere with the completion of treatment&#xD;
             according to this protocol are not eligible&#xD;
&#xD;
          -  Patients who have a known allergy to any of the study medications, their analogues, or&#xD;
             excipients in the various formulations of any agent are not eligible&#xD;
&#xD;
          -  Patients who have a known gastrointestinal (GI) disease or GI procedure that could&#xD;
             interfere with the oral absorption or tolerance of ixazomib including difficulty&#xD;
             swallowing are not eligible&#xD;
&#xD;
          -  Patients who have been diagnosed or treated for another malignancy within 2 years&#xD;
             before study enrollment or previously diagnosed with another malignancy and have any&#xD;
             evidence of residual disease are not eligible; NOTE: Patients with nonmelanoma skin&#xD;
             cancer or carcinoma in situ of any type are not excluded if they have undergone&#xD;
             complete resection&#xD;
&#xD;
          -  Patients who have &gt;= grade 3 peripheral neuropathy, or grade 2 with pain on clinical&#xD;
             examination during the screening period are not eligible&#xD;
&#xD;
          -  Patients who are participating in other clinical trials, including those with other&#xD;
             investigational agents not included in this trial, within 30 days of registration and&#xD;
             throughout the duration of this trial are not eligible&#xD;
&#xD;
          -  Female patients who are nursing or have a positive pregnancy test during screening are&#xD;
             not eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Pro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University</name>
      <address>
        <city>Medford</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2015</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Barbara Pro</investigator_full_name>
    <investigator_title>Barbara Pro, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Plasmablastic Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Immunoblastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 13, 2021</submitted>
    <returned>October 8, 2021</returned>
    <submitted>November 10, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

